Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.34 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10083540 | 0.91 | RXFP1 (0.35) | RXFP1CSF1RKDM4EHPGDCYP2C19 | |
| SCHEMBL10072571 | 0.89 | LMNA (0.34) | KDM4EHPGDALDH1A1KMT2AMEN1 | |
| SCHEMBL761092 | 0.88 | ALDH1A1 (0.39) | RXFP1CSF1RKDM4EHPGDCYP2C19 | |
| SCHEMBL19039323 | 0.87 | HTR3A (0.31) | ALDH1A1MAPK1 | |
| SCHEMBL9927991 | 0.87 | HTR3A (0.31) | ALDH1A1MAPK1 | |
| SCHEMBL7835307 | 0.85 | PRKD3 (0.40) | RXFP1CSF1RKDM4EHPGDCYP2C19 | |
| SCHEMBL12694820 | 0.83 | HTR3A (0.32) | — | |
| SCHEMBL12458209 | 0.82 | HTR3A (0.32) | — | |
| SCHEMBL708977 | 0.82 | RXFP1 (0.37) | RXFP1CSF1RKDM4EHPGDCYP2C19 | |
| SCHEMBL7831785 | 0.82 | RXFP1 (0.37) | RXFP1CSF1RKDM4EHPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676774-B2 | Compounds and compositions for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC (US) | 2017-04-13 | — | — | US | disclosed |
| US-20150150858-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8765954-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120245198-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS INC. | 2012-09-27 | — | — | US | disclosed |
| US-8124773-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150858-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | RXFP1 4592/4885CSF1R 4017/4885KDM4E 1871/4885 |
| US-20120245198-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | RXFP1 4592/4885CSF1R 4017/4885KDM4E 1871/4885 |
| US-20170101404-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | RXFP1 4592/4885CSF1R 4017/4885KDM4E 1871/4885 |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | RXFP1 4592/4885CSF1R 4017/4885KDM4E 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.